Submitted:
11 June 2026
Posted:
11 June 2026
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
2.1. Study Design and Patient Selection
2.2. Clinical Assessment and Laboratory Measurements
2.3. Statistical Analysis
3. Results
3.1. Baseline Demographic and Clinical Characteristics
3.2. Comorbidity Profile
3.3. Emergency Department Treatment Interventions
3.4. Laboratory Parameters at Admission
3.5. Infection Source Distribution
3.6. Clinical Outcomes
4. Discussion
Study Limitations
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Lafon, T.; Weingart, M.; Vaidie, J.; Calfee, C. S.; Jacob, S. T.; Freund, Y.; Shapiro, N. I.; Barraud, O.; Monneret, G.; van der Poll, T.; Fromage, Y.; François, B., Challenges in early detection and prognostication of sepsis: new approaches from the emergency department and intensive care unit. EClinicalMedicine 2026, 94, 103864. [CrossRef]
- Guarino, M.; Perna, B.; Cesaro, A. E.; Maritati, M.; Spampinato, M. D.; Contini, C.; De Giorgio, R., 2023 Update on Sepsis and Septic Shock in Adult Patients: Management in the Emergency Department. Journal of Clinical Medicine 2023, 12 (9), 3188. [CrossRef]
- Singer, M.; Deutschman, C. S.; Seymour, C. W.; Shankar-Hari, M.; Annane, D.; Bauer, M.; Bellomo, R.; Bernard, G. R.; Chiche, J. D.; Coopersmith, C. M.; Hotchkiss, R. S.; Levy, M. M.; Marshall, J. C.; Martin, G. S.; Opal, S. M.; Rubenfeld, G. D.; van der Poll, T.; Vincent, J. L.; Angus, D. C., The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). Jama 2016, 315 (8), 801-10. [CrossRef]
- Evans, L.; Rhodes, A.; Alhazzani, W.; Antonelli, M.; Coopersmith, C. M.; French, C.; Machado, F. R.; McIntyre, L.; Ostermann, M.; Prescott, H. C.; Schorr, C.; Simpson, S.; Wiersinga, W. J.; Alshamsi, F.; Angus, D. C.; Arabi, Y.; Azevedo, L.; Beale, R.; Beilman, G.; Belley-Cote, E.; Burry, L.; Cecconi, M.; Centofanti, J.; Coz Yataco, A.; De Waele, J.; Dellinger, R. P.; Doi, K.; Du, B.; Estenssoro, E.; Ferrer, R.; Gomersall, C.; Hodgson, C.; Møller, M. H.; Iwashyna, T.; Jacob, S.; Kleinpell, R.; Klompas, M.; Koh, Y.; Kumar, A.; Kwizera, A.; Lobo, S.; Masur, H.; McGloughlin, S.; Mehta, S.; Mehta, Y.; Mer, M.; Nunnally, M.; Oczkowski, S.; Osborn, T.; Papathanassoglou, E.; Perner, A.; Puskarich, M.; Roberts, J.; Schweickert, W.; Seckel, M.; Sevransky, J.; Sprung, C. L.; Welte, T.; Zimmerman, J.; Levy, M., Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med 2021, 47 (11), 1181-1247. [CrossRef]
- Trebuian, C. I.; Brici, O. M.; Sutoi, D.; Popa, D. I.; Chioibas, D. R.; Mederle, O. A., Lactate Levels and Clearance: Key Predictors of Prognosis for COVID-19 and Non-COVID-19 Septic Shock Patients in the Emergency Department. Clin Pract 2024, 14 (3), 834-845. [CrossRef]
- Rio, P.; Caldarelli, M.; Miccoli, E.; Guazzarotti, G.; Gasbarrini, A.; Gambassi, G.; Cianci, R., Sex Differences in Immune Responses to Infectious Diseases: The Role of Genetics, Hormones, and Aging. Diseases 2025, 13 (6). [CrossRef]
- Araújo, M.; Mendes-Frias, A.; Silvestre, R., Sex differences in immune modulation: implications for infection, inflammation, and nutritional supplementation. Biology of Sex Differences 2026, 17 (1), 61. [CrossRef]
- Lakbar, I.; Einav, S.; Lalevée, N.; Martin-Loeches, I.; Pastene, B.; Leone, M., Interactions between Gender and Sepsis-Implications for the Future. Microorganisms 2023, 11 (3). [CrossRef]
- Mewes, C.; Runzheimer, J.; Böhnke, C.; Büttner, B.; Hinz, J.; Quintel, M.; Mansur, A., Association of Sex Differences with Mortality and Organ Dysfunction in Patients with Sepsis and Septic Shock. J Pers Med 2023, 13 (5). [CrossRef]
- Dias, S. P.; Brouwer, M. C.; van de Beek, D., Sex and Gender Differences in Bacterial Infections. Infect Immun 2022, 90 (10), e0028322. [CrossRef]
- Falagas, M. E.; Mourtzoukou, E. G.; Vardakas, K. Z., Sex differences in the incidence and severity of respiratory tract infections. Respiratory Medicine 2007, 101 (9), 1845-1863. [CrossRef]
- Pepe, F.; Pinelli, M. A.; Giuliante, S.; Sabatino, F.; Sari, L.; Visintainer, S.; Fuciarelli, L.; Innocenti, F., Sepsis in the Emergency Department: Different Faces, Same Fate? A Sex-Based Prognostic Analysis. International Journal of Molecular Sciences 2026, 27 (9), 3753. [CrossRef]
- Wanrooij, V. H. M.; Cobussen, M.; Stoffers, J.; Buijs, J.; Bergmans, D.; Zelis, N.; Stassen, P. M., Sex differences in clinical presentation and mortality in emergency department patients with sepsis. Ann Med 2023, 55 (2), 2244873. [CrossRef]
- Trebuian, C. I.; Popa, D.; Buleu, F.; Sutoi, D.; Williams, C. G.; Crintea, I. N.; Chioibas, R. D.; Iancu, A.; Ciolac, L.; Mederle, O. A., COVID-19 Related Acute Respiratory Distress Syndrome versus Classical Acute Respiratory Distress Syndrome Patients: Inflammatory Biomarkers as Predictors of Mortality in Pulmonary Septic Shock. Int J Gen Med 2024, 17, 3337-3347. [CrossRef]
- Hajji, O.; Behnes, M.; Rusnak, J.; Jawhar, S.; Brück, L. M.; Dulatahu, F.; Hetjens, S.; Abumayyaleh, M.; Akin, I.; Schupp, T.; Weidner, K., Age- and Sex-Related Outcomes in Patients with Sepsis or Septic Shock: A Prospective Monocentric Cohort Study. Journal of Clinical Medicine 2026, 15 (11), 4203. [CrossRef]
- Seymour, C. W.; Liu, V. X.; Iwashyna, T. J.; Brunkhorst, F. M.; Rea, T. D.; Scherag, A.; Rubenfeld, G.; Kahn, J. M.; Shankar-Hari, M.; Singer, M.; Deutschman, C. S.; Escobar, G. J.; Angus, D. C., Assessment of Clinical Criteria for Sepsis: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). Jama 2016, 315 (8), 762-74.
- Roy, A.; Krishnasamy, V.; Mitra, S.; Banerjee, S.; Dutta, T. K.; Kumar, N. S.; Roy, S., Impact of cardiovascular and metabolic comorbidities on severity and outcomes of hospital-acquired sepsis in intensive care patients: a case-control study. BMC Infect Dis 2026, 26 (1). [CrossRef]
- Foxman, B., Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med 2002, 113 Suppl 1A, 5s-13s.
- Vadakedath, S.; Kandi, V.; Mohapatra, R. K.; Pinnelli, V. B. K.; Yegurla, R. R.; Shahapur, P. R.; Godishala, V.; Natesan, S.; Vora, K. S.; Sharun, K.; Tiwari, R.; Bilal, M.; Dhama, K., Immunological aspects and gender bias during respiratory viral infections including novel Coronavirus disease-19 (COVID-19): A scoping review. J Med Virol 2021, 93 (9), 5295-5309. [CrossRef]
- Agrawal, S.; Salazar, J.; Tran, T. M.; Agrawal, A., Sex-Related Differences in Innate and Adaptive Immune Responses to SARS-CoV-2. Frontiers in Immunology 2021, Volume 12 - 2021. [CrossRef]
- McClements, L.; Kautzky-Willer, A.; Kararigas, G.; Ahmed, S. B.; Stallone, J. N., The role of sex differences in cardiovascular, metabolic, and immune functions in health and disease: a review for “Sex Differences in Health Awareness Day”. Biology of Sex Differences 2025, 16 (1), 33. [CrossRef]



| Group | N | Mean | SD | SE | Coefficient of variation | Mean Rank | Sum Rank | |
| Age (years) | Female | 100 | 72.130 | 15.263 | 1.526 | 0.212 | 129.14 | 12,914 |
| Male | 113 | 64.248 | 13.664 | 1.285 | 0.213 | 87.41 | 9,877 | |
| SBP (mmHg) | Female | 100 | 123.320 | 26.081 | 2.608 | 0.211 | 106.00 | 10,600 |
| Male | 113 | 123.496 | 27.049 | 2.545 | 0.219 | 107.89 | 12,192 | |
| DBP (mmHg) | Female | 100 | 67.200 | 12.607 | 1.261 | 0.188 | 94.39 | 9,439 |
| Male | 113 | 72.274 | 14.083 | 1.325 | 0.195 | 118.16 | 13,352 | |
| Saturation on room air (%) | Female | 100 | 94.560 | 5.151 | 0.515 | 0.054 | 111.27 | 11,127 |
| Male | 113 | 94.248 | 4.556 | 0.429 | 0.048 | 103.23 | 11,665 | |
| Body Temperature (°C) | Female | 100 | 37.059 | 0.916 | 0.092 | 0.025 | 110.35 | 11,035 |
| Male | 113 | 37.055 | 1.015 | 0.095 | 0.027 | 104.04 | 11,756 | |
| GCS | Female | 100 | 13.910 | 2.257 | 0.226 | 0.162 | 107.04 | 10,704 |
| Male | 113 | 13.841 | 2.313 | 0.218 | 0.167 | 106.96 | 12,087 |
| Sample | ||||
|---|---|---|---|---|
| Comorbidities | Female (n=100) | Male (n=113) | p value | |
| Cardiovascular disease, n (%) | 72 | 59 | 0.003* | |
| (72.00 %) | (52.21 %) | |||
| Pulmonary disease, n (%) | 27 | 43 | 0.087 | |
| (27.00 %) | (38.05 %) | |||
| Diabetes mellitus, n (%) | 22 | 29 | 0.532 | |
| (22.00 %) | (25.66 %) | |||
| Renal disease, n (%) | 54 | 46 | 0.052 | |
| (54.00 %) | (40.70 %) | |||
| Cerebral disease, n (%) | 26 | 24 | 0.413 | |
| (26.00 %) | (21.23 %) | |||
| Liver disease, n (%) | 21 | 24 | 0.966 | |
| (21.00 %) | (21.23 %) | |||
| Malignant disease, n (%) | 29 | 32 | 0.913 | |
| (29.00 %) | (28.31 %) | |||
| Sample | ||||
|---|---|---|---|---|
| Treatment | Female (n=100) |
Male (n=113) |
p value | |
| Supplemental oxygen, n (%) | 28 | 32 | 0.959 | |
| (28.00 %) | (28.31 %) | |||
| Vasopressor therapy, n (%) | 26 | 15 | 0.019 | |
| (26.00 %) | (13.27 %) | |||
| Broad-spectrum antibiotics, n (%) | 99 | 88 | 0.001* | |
| (99.00 %) | (77.87 %) | |||
| Group | N | Mean | SD | SE | Coefficient of variation | Mean Rank | Sum Rank | |
| Hemoglobin (g/dL) | Female | 100 | 11.358 | 2.397 | 0.240 | 0.211 | 94.19 | 9,419 |
| Male | 113 | 12.517 | 3.462 | 0.326 | 0.277 | 118.34 | 13,372 | |
| Leukocytes (×10⁹/L) | Female | 100 | 19.479 | 35.659 | 3.566 | 1.831 | 105.01 | 10,501 |
| male | 113 | 15.633 | 8.530 | 0.802 | 0.546 | 108.77 | 12,291 | |
| Neutrophils (×10⁹/L) | Female | 100 | 13.012 | 10.312 | 1.031 | 0.792 | 102.55 | 10,255 |
| Male | 113 | 13.973 | 10.790 | 1.015 | 0.772 | 110.94 | 12,536 | |
| Lymphocytes (×10⁹/L) | Female | 100 | 4.538 | 32.407 | 3.241 | 7.142 | 104.29 | 10,429 |
| Male | 113 | 1.163 | 0.802 | 0.075 | 0.689 | 109.40 | 12,363 | |
| NLR | Female | 100 | 15.110 | 10.823 | 1.082 | 0.716 | 106.80 | 10,680 |
| Male | 113 | 17.425 | 19.913 | 1.873 | 1.143 | 107.18 | 12,112 | |
| C-reactive protein (mg/L) | Female | 100 | 169.224 | 129.815 | 12.981 | 0.767 | 101.29 | 10,129 |
| Male | 113 | 197.188 | 147.439 | 13.870 | 0.748 | 112.06 | 12,663 | |
| Procalcitonin (ng/mL) | Female | 100 | 16.662 | 41.973 | 4.197 | 2.519 | 110.36 | 11,036 |
| Male | 113 | 12.346 | 31.347 | 2.949 | 2.539 | 104.03 | 11,756 |
| Sample | ||||
|---|---|---|---|---|
| Infection starting point | Female (n=100) | Male (n=113) | p value | |
| Respiratory, n (%) | 22 | 36 | 0.107 | |
| (22.00 %) | (31.85 %) | |||
| Digestive, n (%) | 22 | 25 | 0.983 | |
| (22.00 %) | (22.12 %) | |||
| Cutaneous/soft-tissue, n (%) | 5 | 11 | 0.532 | |
| (5.00 %) | (9.73 %) | |||
| Urinary, n (%) | 51 | 39 | 0.015* | |
| (51.00 %) | (34.51 %) | |||
| Unknown, n (%) | 17 | 18 | 0.56 | |
| (17.00 %) | (15.92 %) | |||
| Sample | ||||
|---|---|---|---|---|
| Outcome | Female (n=100) |
Male (n=113) |
p value | |
| ICU admission, n (%) | 16 | 15 | 0.573 | |
| (16.00 %) | (13.27 %) | |||
| Ward admission, n (%) | 76 | 91 | 0.423 | |
| (76.00 %) | (80.53 %) | |||
| In-hospital mortality, n (%) | 8 | 7 | 0.607 | |
| (8.00 %) | (6.20 %) | |||
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).